UK’s Bingham expects Omicron vaccine impact to be known in a week | Inquirer News
Close  

UK’s Bingham expects Omicron vaccine impact to be known in a week

/ 11:16 PM December 01, 2021
A nurse prepares a vaccination at the Hartlepool Town Hall Theatre vaccination centre, as the spread of the coronavirus disease (COVID-19) continues in Hartlepool

A nurse prepares a vaccination at the Hartlepool Town Hall Theatre vaccination centre, as the spread of the coronavirus disease (COVID-19) continues in Hartlepool, Britain, Dec. 1, 2021. (REUTERS)

LONDON — Kate Bingham, the former head of the UK’s COVID-19 Vaccine Taskforce who secured millions of doses for the country, said scientists should know within a week whether existing shots are effective against the Omicron variant of the coronavirus.

Bingham, a venture capitalist who backed multiple vaccines at the start of the pandemic to secure early access for Britain, said she currently expected that the leading shots would still show efficacy.

ADVERTISEMENT

“The question is do they have the same level of efficacy?” she said in an interview at the Reuters Next conference on Wednesday.

Bingham, who has returned to her role as managing partner at SV Health Investors, said Britain had built up the capability to quickly test existing vaccines against new variants.

FEATURED STORIES

“It’s not something you can do overnight, but we will get data, I would have thought within a week as to whether or not the vaccines work or don’t,” she said.

Under Bingham’s leadership, the UK task force ordered vaccines as they were still being trialed, securing supplies from Pfizer, AstraZeneca, Moderna, and others to give Britain a head start in the rollout.

She said on Wednesday that she had backed the vaccine from French company Valneva, which differs from others by relying on an inactivated virus similar to flu vaccines because having a varied portfolio would be useful when variants emerged.

Britain has since canceled the order.

“The idea of having that as a potential vaccine in our portfolio, knowing it was going to come on stream later than the earlier ones, was precisely that you could deal with variants,” she said.

She added that “unfortunately” the Valneva contract had been canceled. “I wasn’t part of the decision so I don’t know the basis of it,” she said. “But I would have thought that was a useful vaccine to have in our panoply of tools to actually address variants and future pandemic strains.”

ATM

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19 Omicron variant, Kate Bingham, vaccine efficacy vs Omicron variant
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.